As filed with the Securities
and Exchange Commission on August 27, 2025
Registration No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
QUOIN
PHARMACEUTICALS LTD.
(Exact name of registrant as specified in its charter)
| State of Israel |
92-2593104 |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
42127 Pleasant
Forest Court
Ashburn, VA 20148-7349
Tel: (703) 980-4182
(Address of Principal Executive Offices) (Zip Code)
2025 Equity Incentive
Plan
(Full title of the plan)
Dr. Michael
Myers
Chief Executive Officer
Quoin Pharmaceuticals Ltd.
42127 Pleasant Forest Ct
Ashburn, VA 20148
(Name and address of agent for service)
Tel: 703-980-4182
(Telephone number, including area code, of agent for service)
Copies to:
|
Melissa Palat Murawsky
Peter I. Tsoflias
Blank Rome LLP
One Logan Square
130 North 18th Street
Philadelphia, PA 19103
Tel: (215) 569-5500 |
Jonathan Irom, Adv.
Matthew Rudolph, Adv.
Meitar | Law Offices
16 Abba Hillel Silver Rd.
Ramat Gan 5250608, Israel
Tel: +972-3-610-3100 |
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of
“large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ¨ |
Accelerated filer ¨ |
| Non-accelerated
filer x |
Smaller reporting company x |
| |
Emerging
growth company ¨ |
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
PART I
INFORMATION
REQUIRED IN THE Section 10(a) Prospectus
The document(s) containing the information specified in Part I
of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended
(the “Securities Act”).
PART II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed by Quoin Pharmaceuticals Ltd. (the “Registrant”)
with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:
| · | The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 13, 2025 (the “Form 10-K”); |
| · | The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 13, 2025; |
| · | The Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Commission on August 7, 2025; |
| · | The Registrant’s Current Reports on
Form 8-K filed with the Commission on January 6,
2025, January 16,
2025, January 23,
2025, February 4,
2025, February 27,
2025, March 20,
2025, April 2,
2025, April 4,
2025, April 4,
2025, April 30,
2025, May 21,
2025, May 23,
2025, June 4,
2025, June 20,
2025, June 25,
2025, July 8,
2025, August 21,
2025 and August 27, 2025; and |
| · | The description of the Registrant’s American Depositary Shares (“ADSs”)
representing the ordinary shares set forth in Exhibit 4.15 to the Form 10-K, including any amendments or reports filed for the
purpose of updating such description. |
In addition, all documents subsequently filed
by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement on Form S-8
(the “Registration Statement”) which indicates that all securities offered have been sold or which deregisters all securities
then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the
date of the filing of such documents. The Registrant is not incorporating by reference any document or portion thereof, whether specifically
listed above or to be filed in the future, that is not deemed “filed” with the Commission.
Any statement contained in a document incorporated
or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement
to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be
incorporated by reference herein), modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed,
except as so modified or superseded, to constitute a part of this Registration Statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Under the Israeli Companies Law, 5759–1999
(the “Companies Law”), a company may not exculpate an Office Holder from liability for a breach of the duty of loyalty. An
Israeli company may exculpate an Office Holder in advance from liability to the company, in whole or in part, for damages caused to the
company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association.
The Registrant’s articles of association include such a provision. An Israeli company may not exculpate in advance a director from
liability arising out of a prohibited dividend or distribution to shareholders.
Under the Companies Law, an Israeli company may
indemnify an Office Holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an Office
Holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include
a provision authorizing such indemnification, which the Registrant’s do:
| · | financial liability imposed on him or her in
favor of another person pursuant to a judgment, including a settlement or arbitrator’s award approved by a court. However, if an
undertaking to indemnify an Office Holder with respect to such liability is provided in advance, then such an undertaking must be limited
to events which, in the opinion of the board of directors, can be reasonably
foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria
determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen
events and amount or criteria; |
| · | reasonable litigation expenses, including attorneys’
fees, incurred by the Office Holder (1) as a result of an investigation or proceeding instituted against him or her by an authority
authorized to conduct such investigation or proceeding, provided that (a) no indictment was filed against such Office Holder as a
result of such investigation or proceeding; and (b) no financial liability, such as a criminal penalty, was imposed upon him or her
as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed,
it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; |
| · | reasonable litigation expenses, including attorneys’
fees, incurred by the Office Holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf,
or by a third party, or in connection with criminal proceedings in which the Office Holder was acquitted, or as a result of a conviction
for an offense that does not require proof of criminal intent; and |
| · | expenses, including reasonable litigation expenses
and legal fees, incurred by an Office Holder in relation to an administrative proceeding instituted against such Office Holder, or certain
compensation payments made to an injured party imposed on an Office Holder by an administrative proceeding, pursuant to certain provisions
of the Israeli Securities Law, 1968 (the “Israeli Securities Law”). |
Under the Companies Law and the Israeli Securities
Law, a company may insure an Office Holder against the following liabilities incurred for acts performed by him or her as an Office Holder
if and to the extent provided in the company’s articles of association:
| · | a breach of the duty of loyalty to the company,
provided that the Office Holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; |
| · | a breach of duty of care to the company or to
a third party, including a breach arising out of the negligent conduct of the Office Holder; and |
| · | a financial liability imposed on the Office Holder
in favor of a third party. |
Under the Registrant’s articles of association,
the Registrant may insure an Office Holder against the aforementioned liabilities as well as the following liabilities:
| · | a breach of duty of care to the company or to
a third party; |
| · | any other action against which the Registrant
is permitted by law to insure an Office Holder; |
| · | expenses incurred and/or paid by the Office Holder
in connection with an administrative enforcement procedure under any applicable law including Parts 8(3), 8(4) and 9(1) of the
Israeli Securities Law, and a proceeding according to Section D of Chapter 4 in Part 9 of the Companies Law, including reasonable
litigation expenses and attorney fees; |
| · | a payment to a person injured by a violation
of Section 52BBB(a)(1)(a) of the Israeli Securities Law; and |
| · | expenses incurred in connection with a proceeding
under the Economic Competition Law 5748-1988, including reasonable litigation expenses and attorney fees. |
Under the Companies Law, an Israeli company may
not indemnify, exculpate or insure an Office Holder against any of the following:
| · | a breach of the duty of loyalty, except for indemnification
and insurance for a breach of the duty of loyalty to the company to the extent that the Office Holder acted in good faith and had a reasonable
basis to believe that the act would not harm the company; |
| · | a breach of duty of care committed intentionally
or recklessly, excluding a breach arising solely out of the negligent conduct of the Office Holder; |
| · | an act or omission committed with intent to derive
illegal personal benefit; or |
| · | a fine, civil fine, or other financial sanction
levied against the Office Holder. |
Under the Companies Law, exculpation, indemnification and
insurance of Office Holders in a public company must be approved by the compensation committee and the board of directors and, with
respect to directors and the Chief Executive Officers or under certain circumstances, also by the shareholders. However, under
regulations promulgated under the Companies Law, the insurance of Office Holders does not require shareholder approval and may be
approved by only the compensation committee, if the engagement terms are determined in accordance with the limitations set forth in
the company’s compensation policy, which was approved by the shareholders by the requisite special majority, provided that the
insurance policy is on market terms and the insurance policy is not likely to materially impact the company’s profitability,
assets or obligations.
The Registrant’s articles of association
permit it to exculpate, indemnify and insure its Office Holders to the fullest extent permitted or to be permitted by the Companies Law
and the Israeli Securities Law.
Upon the recommendation of the Registrant’s
compensation committee, its board of directors has approved, and its shareholders have approved, at the annual general meeting held on
April 12, 2022, the form of indemnification and release agreements to be entered into with each of the Registrant’s current
and future directors and executive officers exculpating them, to the fullest extent permitted by law and the Registrant’s articles
of association, and undertaking to indemnify them to the fullest extent permitted by law and the Registrant’s articles of association.
This indemnification will be limited to events determined as foreseeable by the board of directors based on the Registrant’s activities,
and to an amount or according to criteria determined by the board of directors and the Registrant’s compensation committee as reasonable
under the circumstances.
The maximum indemnification amount set forth in
the Registrant’s indemnification and release agreements during any period of three years in the aggregate for all of the covered
directors and executive officers, is limited to an amount equal to the higher of: (i) $35,000,000 and (ii) 25% of the Registrant’s
total shareholders’ equity as reflected in the Registrant’s most recent financial statements as of the time of the actual
payment of indemnification is made.
In the opinion of the SEC, indemnification of
directors and other Office Holders for liabilities arising under the Securities Act, however, is against public policy and therefore unenforceable.
The Registrant has obtained directors’ and
officers’ liability insurance for the benefit of its Office Holders and intend to continue to maintain such coverage and pay all
premiums thereunder to the fullest extent permitted by the Companies Law.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
The Exhibits to this Registration Statement are listed in the Exhibit Index
and incorporated herein by reference.
Item 9. Undertakings.
(a) The undersigned Registrant
hereby undertakes:
| |
(1) |
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: |
(i) To include any prospectus required by Section 10(a)(3) of
the Securities Act;
(ii) To reflect in the prospectus
any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in this
Registration Statement; and
(iii) To include any material information
with respect to the Plan of Distribution not previously disclosed in this Registration Statement or any material change to such information
in this Registration Statement.
provided, however,
that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or
Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.
| |
(2) |
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| |
(3) |
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
(b) The
undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where
applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act)
that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(h) Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant
to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
INDEX
TO EXHIBITS
| No. |
|
Description of Exhibit |
| |
|
|
| 4.1 |
|
Amended and Restated Articles of Association of Quoin
Pharmaceuticals Ltd., as amended (incorporated by reference to Exhibit 3.1 to Form 10-K filed with the Commission on March 13,
2025). |
| |
|
|
| 4.2 |
|
Amendment to Amended and Restated Articles of Association
of Quoin Pharmaceuticals Ltd., adopted on August 21, 2025 (incorporated by reference to Exhibit 3.1 to Form 8-K filed
with the Commission on August 21, 2025). |
| |
|
|
| 4.3 |
|
Form of Deposit Agreement between Cellect Biotechnology
Ltd. (n/k/a Quoin Pharmaceuticals Ltd.), The Bank of New York Mellon as Depositary, and owners and holders from time to time of ADSs
issued thereunder (incorporated by reference to Exhibit 4.1 to Registration Statement on Form F-1/A as filed with the Commission
on July 26, 2016). |
| |
|
|
| 4.4* |
|
2025 Equity Incentive Plan of Quoin Pharmaceuticals, Ltd. |
| |
|
|
| 5.1* |
|
Legal Opinion of Meitar | Law Offices, Israeli
legal counsel to Quoin Pharmaceuticals Ltd. |
| |
|
|
| 23.1* |
|
Consent of Marcum LLP, Certified Public Accountants |
| |
|
|
| 23.2* |
|
Consent of Meitar | Law Offices (included in Exhibit 5.1) |
| |
|
|
| 24.1* |
|
Power of Attorney (included on signature page) |
| |
|
|
| 107* |
|
Filing Fee Table |
*Filed herewith
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing this Registration Statement and has duly caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in Ashburn, Virginia on August 27, 2025.
| |
Quoin Pharmaceuticals Ltd. |
| |
|
|
|
| |
By: |
/s/ Dr. Michael Myers |
| |
|
Name: |
Dr. Michael Myers |
| |
|
Title: |
Chief Executive Officer |
POWER
OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose
signature appears below hereby constitutes and appoints Dr. Michael Myers and Denise Carter, and each of them, his or her true
and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place
and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments),
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and
necessary to be done in and about the premises, as fully for all intents and purposes as he or she might or could do in person, hereby
approving, ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their substitute or substitutes,
may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
Signature |
|
Title |
|
Date |
| |
|
|
|
/s/ Dr. Michael
Myers
Dr. Michael Myers |
|
Chairman and Chief Executive Officer
(Principal Executive Officer) |
|
August 27, 2025 |
| |
|
|
| /s/ Sally Lawlor |
Chief Financial Officer |
|
| Sally Lawlor |
|
(Principal Financial Officer and Principal Accounting Officer) |
|
August 27, 2025 |
| |
|
|
| /s/ Denise Carter |
|
|
| Denise Carter |
|
Director and Chief Operating Officer |
|
August 27, 2025 |
| |
|
|
|
|
| /s/ Joseph Cooper |
|
|
| Joseph Cooper |
|
Director |
|
August 27, 2025 |
| |
|
|
| /s/ James Culverwell |
|
|
| James Culverwell |
Director |
|
August 27, 2025 |
| |
|
|
| /s/ Dr. Dennis Langer |
|
|
| Dr. Dennis Langer |
|
Director |
|
August 27, 2025 |
| |
|
|
|
|
| /s/ Natalie Leong |
|
|
| Natalie Leong |
|
Director |
|
August 27, 2025 |
| |
|
|
|
|
| /s/ Michael Sember |
|
|
| Michael Sember |
|
Director |
|
August 27, 2025 |
SIGNATURE
OF AUTHORIZED U.S. REPRESENTATIVE
Pursuant to the Securities Act of 1933, as amended,
the undersigned, the duly authorized representative in the United States of Quoin Pharmaceuticals Ltd., has signed this Registration Statement
in Ashburn, Virginia on August 27, 2025.
| |
Authorized U.S. Representative |
| |
Dr. Michael Myers |
| |
|
|
| |
By: |
/s/ Dr. Michael Myers |
| |
Name: |
Dr. Michael Myers |
| |
Title: |
Chief Executive Officer |
